SCHEMBL4099192

SCHEMBL4099192

COc1ccc(OC)c(OB(O)O)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.65
CA1 P00915 1/20 0.65
CA2 P00918 1/20 0.65
CA7 P43166 1/20 0.65
CA9 Q16790 1/20 0.65
CA14 Q9ULX7 1/20 0.65
ALDH1A1 P00352 6/20 0.50
HPGD P15428 2/20 0.50
RAD52 P43351 1/20 0.50
GAA P10253 2/20 0.47
CYP1A1 P04798 4/20 0.47
CYP1A2 P05177 4/20 0.47
CYP1B1 Q16678 4/20 0.47
MAPT P10636 3/20 0.47
CYP3A4 P08684 2/20 0.47
MEN1 O00255 1/20 0.47
THRB P10828 1/20 0.47
KMT2A Q03164 1/20 0.47
NFE2L2 Q16236 1/20 0.46
HTT P42858 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30523913 1.00 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL2936012 0.92 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL30702417 0.92 CA12 (0.65) CA12CA1CA2CA7CA9
SCHEMBL2178296 0.86 CA2 (0.61) CA12CA1CA2CA7CA9
SCHEMBL17075740 0.81 CA1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL1943729 0.81 CA1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL29880696 0.81 CA1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL29004580 0.81 CA1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL29066818 0.81 CA1 (0.45) CA12CA1CA2CA7CA9
SCHEMBL28080378 0.81 CA1 (0.45) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP claimed
CN-116761834-A Storage stable epoxy resin composition 澳泽化学特罗斯特贝格有限公司 2023-09-15 CN disclosed
CN-114207024-B Storage stable epoxy resin composition 澳泽化学特罗斯特贝格有限公司 2023-08-22 CN disclosed
CN-101821246-B Tetrazole-substituted arylamide derivatives and uses thereof HOFFMANN LA ROCHE 2013-05-01 CN disclosed
EP-1724294-B1 POLYMER AND POLYMERIC LUMINESCENT ELEMENT COMPRISING THE SAME SUMITOMO CHEMICAL CO (JP) 2012-11-14 EP disclosed
US-8288424-B2 Substituted tetrahydroimidazopyridine compounds and the use thereof in the treatment of pain and other conditions GRUENENTHAL GMBH (DE) 2012-10-16 US disclosed
CN-101821246-A Tetrazole-substituted arylamide derivatives and uses thereof HOFFMANN LA ROCHE 2010-09-01 CN disclosed
CN-101743224-A 7-substituted indole mcl-1 inhibitors ABBOTT LAB 2010-06-16 CN disclosed
US-20090186902-A1 Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions GRUENENTHAL GMBH (DE) 2009-07-23 US disclosed
US-20080274303-A1 Polymer Compound and Polymer Light Emitting Device Using the Same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-11-06 US disclosed
EP-1724294-A1 POLYMER AND POLYMERIC LUMINESCENT ELEMENT COMPRISING THE SAME Sumitomo Chemical Company, Limited (JP) 2006-11-22 EP disclosed
EP-1403251-A1 BIS(2-ARYL-5-PYRIDYL) DERIVATIVE Kowa Co., Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186902-A1 Substituted Tetrahydroimidazopyridine Compounds and the Use Thereof in the Treatment of Pain and Other Conditions HRH4, TRPV1, QDPR CA12 2685/4885CA1 827/4885CA2 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.